ECHO THERAPEUTICS

http://finance.yahoo.com/q/is?s=ecte .. anika amarin xoma (wiedermal) sunesis agenus cell therap. laufen derzeit sehr gut... meine weniger guten.... 4 sc ecte response hab den dreh mit dem rechtzeitigen ausstieg nie ganz gerafft, deshalb immer einen konsequenten sl drin...außer bei den pennys- die zähl ich aber lieber nicht auf ; )) @bolle gar nicht mehr online? deine empfehlungen fehln mir etwas ; )))

http://www.bizjournals.com/philadelphia/news/2011/12/06/echo-therapeutics-announces-securities.html?ana=yfcpc http://finance.yahoo.com/news/Echo-Therapeutics-Present-prnews-4126360534.html?x=0 http://www.bizjournals.com/philadelphia/news/2011/12/06/echo-therapeutics-announces-securities.html?ana=yfcpc http://biz.yahoo.com/e/111227/ecte8-k.html für biotech-interessierte lohnt sich auch ein blick auf folgende werte, in anika und biomarin bin ich selber schon investiert.....in den anderen noch nicht: http://www.ariva.de/anika_therapeutics_inc-aktie http://www.ariva.de/biomarin_pharmaceutical_inc-aktie http://www.ariva.de/amarin_corporation_plc-aktie http://www.ariva.de/acasti_pharma_inc-aktie keine empfehlung, nur ein freundlicher hinweis ; ) gruß alice

http://finance.yahoo.com/news/Echo-Therapeutics-Announces-prnews-544645291.html?x=0&.v=1 Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System Press Release Source: Echo Therapeutics, Inc. On Thursday October 6, 2011, 7:30 am EDT PHILADELPHIA, Oct. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq:ECTE - News), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System. Data from the study confirm that Symphony successfully monitors patient glucose levels and continues to demonstrate improvements in clinical performance. Echo plans to conduct a study in patients with diabetes during the fourth quarter, followed by a study in critical care patients shortly thereafter. "The results of this study demonstrate that this next generation of Symphony successfully monitors glucose levels and has the potential to be an important tool for tracking and trending of glucose. The adoption of CGM is growing rapidly in diabetes management, as is frequent glucose testing in critical care patients, as medical literature continues to underscore the need for better glucose control to improve patient outcomes," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We are excited about these results and the potential for Symphony and we expect similar, positive results from the two additional studies in diabetics and critical care patients in the coming months." Study Design The feasibility study was designed to evaluate the performance of the Symphony tCGM System. Twelve (12) adult subjects, each without a history of diabetes, were evaluated. The skin of each subject was prepared using Prelude and a Symphony tCGM biosensor was applied to the skin site. Venous reference blood samples were taken from intravenous lines at 15-minute intervals for 24 hours and measured on a YSI 2300 STAT Plus Glucose Analyzer and a commercially available, professional-use glucometer. The study data was blinded to study subjects and study personnel. At the conclusion of the 24-hour study period, the test skin sites were inspected for redness or other undesirable effects. Analytical Methods Continuous data from the Symphony tCGM System were compared to reference measurements from a YSI 2300 STAT Plus Glucose Analyzer and professional-use blood glucose test system. Those reference measurements were paired with the Symphony results through a data analysis algorithm. The primary statistical analysis tools used to evaluate the performance of Symphony were the Continuous Glucose-Error Grid analysis (CG-EGA) and Mean Absolute Relative Difference (MARD). The CG-EGA is a categorization of all data pairs based on the clinical significance of the accuracy. Accurate readings result in the same clinical decision when based on the CGM value versus the blood glucose value. Benign errors lead to the same clinical outcome as accurate readings even though the actual clinical decision may differ. Erroneous readings lead to clinical errors. CGM performance is measured as the sum of accurate readings and benign errors. Numerical accuracy is measured using MARD, an error calculation tool that was used to measure the absolute value of the average relative difference between Symphony and the reference measurements, on a percentage basis. Study Results Using over 1,600 Symphony tCGM glucose readings from the 12 study subjects paired with reference blood glucose measurements, CG-EGA showed that 98.3% of the readings were clinically accurate and 1.2% were benign errors with a combined A+B of 99.5%. The MARD for the study was 10.5%. Values for blood glucose measurements ranged from 64 to 212 mg/dL. There were no adverse events reported from the Prelude skin permeation or the Symphony tCGM biosensor.

http://finance.yahoo.com/news/Echo-Therapeutics-to-Present-prnews-1846222034.html?x=0&.v=1 PHILADELPHIA, Sept. 20, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ:ECTE - News), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Sixth Annual JMP Securities Healthcare Conference. Dr. Mooney will make a presentation to prospective corporate partners and investors on Tuesday, September 27th at 8:30 AM ET. The Company's presentation will be delivered at The St. Regis New York Hotel in New York City. About Echo Therapeutics Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. For More Information: Christine Olimpio Director, Corporate Communications (215) 717-4104